

#### TREATMENT PROTOCOL

S-136

### **RESPIRATORY DISTRESS**

Date: 7/1/2025 Page 1 of 1

BLS ALS

- Ensure patent airway
- Reassurance
- Dislodge any airway obstruction. Treat per Airway Obstruction Protocol (S-121)
- O2 saturation
- O2 and/or ventilate PRN
- Transport in position of comfort
- Carboxyhemoglobin monitor PRN, if available
- May assist patient to self-medicate own prescribed MDI once only. BH contact required for additional dose(s)

## Toxic inhalation (e.g., CO exposure, smoke, gas)

- Move patient to safe environment
- 100% O<sub>2</sub> via mask
- Consider transport to facility with hyperbaric chamber for suspected CO poisoning for unconscious or pregnant patients

### Croup-like cough

 Aerosolized saline or water 5 mL via O2powered nebulizer/mask, MR PRN

- Monitor/ECG
- Capnography
- IV/IO <sup>®</sup>
- Intubate PRN
- NG/OG PRN

#### Suspected CHF/cardiac origin

- NTG<sup>1</sup> SL
  - If systolic BP ≥100 but <150: NTG 0.4 mg SL, MR q3-5 min <sup>®</sup>
  - If systolic BP ≥150: NTG 0.8 mg SL, MR q3-5 min <sup>®</sup>
- CPAP 5-10 cmH<sub>2</sub>O

### Suspected non-cardiac origin<sup>2</sup>

- Albuterol/Levalbuterol 6 mL via nebulizer, MR ®
- Ipratropium bromide 2.5 mL 0.02% via nebulizer added to first dose of albuterol/levalbuterol
- CPAP 5-10 cmH<sub>2</sub>O

### **Unable to tolerate CPAP**

• Midazolam 0.5-1 mg IM/IN/IV

## Severe respiratory distress/failure or inadequate response to nebulized treatments consider

History of asthma or suspected allergic reaction

• Epinephrine 1:1,000 (1 mg/mL) 0.5 mg IM, MR x2 q5 min <sup>®</sup>

# Intubated patients with agitation and potential for airway compromise

• Midazolam 2-5 mg IM/IN/IV/IO, MR x1 in 5-10 min

#### Notes:

- For respiratory arrest, immediately start BVM ventilation
- Use caution with CPAP in patients with COPD; start low and titrate pressure
- Epinephrine IM: Use caution if known cardiac history, history of hypertension, SBP >150 mmHg, or age >40
- Fireline paramedics without access to O<sub>2</sub> may use MDI

<sup>&</sup>lt;sup>1</sup> NTG is contraindicated in patients who have taken erectile dysfunction medications such as sildenafil (Viagra®), tadalafil (Cialis®), and vardenafil (Levitra®) within 48 hours; and pulmonary hypertension medications such as sildenafil (Revatio®), and epoprostenol sodium (Flolan®) and (Veletri®) <sup>2</sup> Infection control: If concerned about aerosolized infectious exposure, substitute with MDI, if available